Skip to content

GLUE MONTE ROSA THERAPEUTICS INC

Follow

COM (common), issuer CIK 1826457

Filings received so far for Q3 2026: 3 13F filers report a position in GLUE shares at 2026-09-30. The quarter is not complete: its 13F deadline is 2026-11-14, and the counts grow as filings arrive.

13D and 13G filers

No 13D or 13G on this security in the data. Structured 13D/G data starts 2024-12-18.

Insider trades

The latest Form 4 transactions, non-derivative.
OwnerDateSharesPriceFiling
Bowen Matthewofficer (Principal Accounting Officer)2026-10-05-13 S$10.56Form 4

13F holders, Q3 2026

Filers in the available 13F reports with a share position at 2026-09-30, filer groups collapsed to one row (method), largest first. Options and principal amounts are left out. A group row states no % of portfolio, since each member reports its own portfolio: the members' percents are listed under it. A value about 1,000 times or 1/1,000 of the price other filers imply is shown as filed but neither ranks the row nor enters a sum.

HolderSharesValue% of portfolioChangeSource
GAMMA Investing LLC2,023$24.1K<0.01%-9113F-HRTimeline
Paladin Partners, LLC1,000$11.9K0.01%013F-HRTimeline
Farther Finance Advisors, LLC489$5.83K<0.01%+17413F-HRTimeline

Events

  • Bowen Matthew sold 13 GLUE shares on 2026-10-05, Form 4 filed 2026-10-06. 0001193125-26-415540

    Accepted , ingested